Division of Hematology/Oncology, Department of Pediatrics, University Hospital of Padova, Padua, Italy.
Urology. 2012 Sep;80(3):698-702. doi: 10.1016/j.urology.2012.05.019. Epub 2012 Jul 10.
To describe clinical and treatment characteristics of renal soft tissue sarcomas in children, we analyzed a series of patients enrolled in the protocols coordinated by the Italian Soft Tissue Sarcoma Committee (STSC).
From 1979 to 2011, 2138 patients with soft tissue sarcomas were registered in different STSC protocols, and 12 had a renal sarcoma: 7 primitive peripheral neuroectodermal tumors, 2 undifferentiated sarcomas, 1 rhabdomyosarcoma, 1 desmoplastic small round cell tumor, and 1 kaposiform hemangioendothelioma. Treatment included conservative surgery, chemotherapy according to the guidelines of the protocols, and radiotherapy for high-risk patients.
Nephrectomy was performed in 11 children resulting in a complete tumor resection in 7. In 4 patients, macroscopical (1) or microscopic (3) tumor residuals remained postoperatively. Tumorectomy was performed in patients with congenital renal agenesis. All patients received chemotherapy. Seven patients also received postoperative radiotherapy. Overall, 9 patients are alive in first complete remission with a median follow-up of 6.1 years (range, 1.3-21.1 years). Two of the 7 patients with primitive peripheral neuroectodermal tumors (pPNETs) died after an early relapse: 1 had metastatic disease at diagnosis and the other was initially misdiagnosed with Wilms tumor (WT). One child with desmoplastic small round cell tumor (DSRCT) is alive with disease. Two patients developed signs of ifosfamide-related nephrotoxicity.
In our analysis, pPNET is the most common type of renal soft tissue sarcoma (STS). Prognosis seems satisfactory with the adoption of an aggressive multidisciplinary approach, especially when complete tumor resection is possible. The replacement of ifosfamide with cyclophosphamide could be considered after nephrectomy.
为了描述儿童肾软组织肉瘤的临床和治疗特征,我们分析了意大利软组织肉瘤委员会(STSC)协调的不同方案中登记的一系列患者。
1979 年至 2011 年,2138 名软组织肉瘤患者在不同的 STSC 方案中登记,其中 12 例为肾肉瘤:7 例原始外周神经外胚层肿瘤、2 例未分化肉瘤、1 例横纹肌肉瘤、1 例促结缔组织增生性小圆细胞肿瘤和 1 例 Kaposiform 血管内皮细胞瘤。治疗包括根据方案指南进行的保肢手术、化疗和高危患者的放疗。
11 例患儿行肾切除术,7 例患儿完全切除肿瘤。4 例患儿术后仍有肉眼(1 例)或镜下(3 例)肿瘤残留。对先天性肾缺如的患儿行肿瘤切除术。所有患儿均接受化疗。7 例患儿还接受术后放疗。总体而言,9 例患者在首次完全缓解后存活,中位随访时间为 6.1 年(范围,1.3-21.1 年)。7 例原始外周神经外胚层肿瘤(pPNET)患者中有 2 例在早期复发后死亡:1 例在诊断时发生转移性疾病,另 1 例最初被误诊为肾母细胞瘤(WT)。1 例促结缔组织增生性小圆细胞肿瘤(DSRCT)患儿存活且疾病仍在进展。2 例患儿出现异环磷酰胺相关肾毒性的迹象。
在我们的分析中,pPNET 是最常见的肾软组织肉瘤(STS)类型。采用积极的多学科方法治疗,特别是在可能完全切除肿瘤的情况下,预后似乎令人满意。在肾切除术后,可以考虑用环磷酰胺替代异环磷酰胺。